The antibody simtuzumab, targeting extracellular LOXL2, has undergone clinical trials in combination with gemcitabine for patients with metastatic pancreatic adenocarcinoma or with FOLFIRI (folinic acid, fluorouracil, and irinotecan) for patients with KRAS mutant colorectal cancer [102, 103]
Bethany Tennant, N.D., a licensed naturopathic physician and certified nutrition specialist, notes that both findings can be true
Rising Number of Clinical Trials Drives Asia-Pacific The APAC clinical trials market size was estimated at US$ 18.87 billion in 2025, projected to increase to US$ 20.42 billion in 2026 and reach US$ 41.33 billion by 2035, showing a healthy CAGR of 7.16% across the forecast years
Understanding GI and Autoimmune Peptide Therapies Peptides are short chains of amino acids that act as signaling molecules in the body
Scar tissue may begin to soften